

<b>SYNAGIS®</b> (palivizumab)	<b>SYNAGIS Prior Authorization Worksheet/Prescription Order Form.</b> Please FAX this completed form to Ohio Medicaid 800-396-4111	Use this form <b>ONLY</b> for Medicaid when Synagis will be administered in the patient's home. No PA is required for fee-for-service Medicaid patients when Synagis is administered in the provider setting.services.
----------------------------------	---	--

**PATIENT INFORMATION (BOLD ITEMS ARE REQUIRED)**

**Patient's (Child's) Name:** \_\_\_\_\_  M  F DOB: \_\_\_\_\_

**Gestational Age (GA)** \_\_\_\_Weeks \_\_\_\_Days **Birth Weight** \_\_\_\_\_ lb/kg **Current Weight** \_\_\_\_\_ lb/kg **Date:** \_\_\_\_\_

Patient's Address: \_\_\_\_\_ Daytime Phone: (\_\_\_\_) \_\_\_\_\_

City/State/Zip: \_\_\_\_\_ Evening Phone: (\_\_\_\_) \_\_\_\_\_

Parent's Name: \_\_\_\_\_ Cell Phone: (\_\_\_\_) \_\_\_\_\_ Best Time to Call: \_\_\_\_\_

Member I.D. Number: \_\_\_\_\_ Other Insurance: \_\_\_\_\_

**Synagis criteria are based on 2009 American Academy of Pediatrics Red Book Guidelines.**  
**MEDICAL AUTHORIZATION CLINICAL CRITERIA** (Please check ALL that apply.)

	<b>Infant/Child's Condition</b>	
<input type="checkbox"/>	≤ 28 6/7 weeks GA (≤ 12 months of age at start of RSV season) [5 dose max]	
<input type="checkbox"/>	29 0/7 – 31 6/7 weeks GA (≤ 6 months of age at start of season) [5 dose max]	
<input type="checkbox"/>	32 0/7 - 34 6/7 weeks GA (<3 months of age at start of RSV season); check all risk factors that apply [3 dose max up to age 90 days]	
<input type="checkbox"/>	Other - Explain: _____	
<b>Risk Factors Consideration</b>		<b>Diagnosis for Consideration (Please Check ALL that apply.)</b>
<input type="checkbox"/>	Siblings < 5 years of age	<input type="checkbox"/> Immunosuppressive/autoimmune disease <input type="checkbox"/> Other _____
<input type="checkbox"/>	On O <sub>2</sub> /Airway Support	<input type="checkbox"/> Severe Neuromuscular Disease <b>Please note:</b>
<input type="checkbox"/>	Child Care Attendance	<input type="checkbox"/> Congenital Abnormalities of Airways <b>Risk Factors for Consideration are subject to clinical and medical review</b>
<input type="checkbox"/>	770.7  (Please document treatment and attach supporting documentation) →	<b>Chronic Lung Disease/BPD: Infants and children ≤ 24 months</b> with Chronic Lung Disease (CLD) who have received treatment for the medical condition in the 6 months prior to RSV season. <b>Diagnosis:</b> _____ <b>Treatment:</b> Mechanical ventilation:    yes / no            Days/Duration _____ Supplemental oxygen:    yes / no            Days/Duration _____ Steroids and/or diuretics:    yes / no            Days/Duration _____ Other                            yes / no            Days/Duration _____
<input type="checkbox"/>	_____ (745–747)	<b>Cardiac (CHD) – Hemodynamically Significant: Infants and children ≤ 24 months</b> with hemodynamically significant cyanotic & acyanotic heart disease with moderate to severe pulmonary hypertension -747.83 or _____ with cyanotic congenital heart disease -746.9 or _____ who are receiving medication to control congestive heart failure -779.89 _____ List medications: Other _____ Dx ICD-9 _____ Comments: _____

**PRESCRIBER INFORMATION (REQUIRED)**

Prescriber's Name: \_\_\_\_\_ Medicaid TIN # \_\_\_\_\_ DEA# \_\_\_\_\_

Practice Name: \_\_\_\_\_ NPI: \_\_\_\_\_

Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone \_\_\_\_\_ Fax: \_\_\_\_\_ Synagis Contact: \_\_\_\_\_

**RX INFORMATION                      SPECIAL INSTRUCTIONS:** \_\_\_\_\_

**Synagis®** (palivizumab) 50 mg and/or 100 mg vials    **Sig:** Inject 15 mg/kg IM one time per month \_\_\_\_\_ **# Doses**

**Date for first Injection:** \_\_\_\_\_                      **Delivery to:**  **Patient's Home**  **MD Office**

**Prescriber's Signature:** \_\_\_\_\_                      **Date:** \_\_\_\_\_

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for return of these documents.